The researchers doing this study are interested in doing the following:
* Biomarker research using fresh tumour tissue and normal blood cells, and if required, tumour tissue already collected. * Bio-banking for use in future research using the collected tumour tissue / blood .
Willingness to submit a blood sample for buffy-coat and at least one tumour biospecimen.
Archived formalin fixed paraffin embedded (FFPE) blocks or slides would only be collected from patients who met CAN-IMPACT-IO study criteria and underwent fresh tumour biopsy/resection following consent but had a tumour specimen deemed insufficient for WGTS. The FFPE sample may be used to provide an alternate source of tumour tissue for WGTS in such cases. Where local centre regulations prohibit submission of blocks of tumour tissue, a predetermined number of unstained slides of representative tumour tissue may substitute the tumour block.
Participant consent for the CAN-IMPACT-IO study must be appropriately obtained in accordance with applicable local and regulatory requirements.
None
Patients enrolled in a specified list of immuno-oncology (IO) therapeutic trials with immune checkpoint inhibitors targeting PD1/PDL1 as single agents or in combination currently active in CCTG.
Cohort
Prospective
Not listed
Establishment of a diverse bank of biological samples, stem cell lines, derivatives, and associated information.
There are no primary endpoints planned for this biobank; endpoints will be specific to research projects that utilize samples/data contained in the biobank. Projects may investigate the biology , etiology, manifestations, progression, risk factors, genetic underpinnings, and treatment of diseases, conditions, and traits.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
